RespireRx Pharmaceuticals Performance
| RSPIDelisted Stock | USD 0.01 0.00 0.00% |
The company holds a Beta of 2.39, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, RespireRx Pharmaceuticals will likely underperform. RespireRx Pharmaceuticals right now holds a risk of 0.0%. Please check RespireRx Pharmaceuticals total risk alpha, potential upside, as well as the relationship between the Potential Upside and kurtosis , to decide if RespireRx Pharmaceuticals will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days RespireRx Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, RespireRx Pharmaceuticals is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 825.00 |
RespireRx |
RespireRx Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.70 in RespireRx Pharmaceuticals on October 7, 2024 and sell it today you would earn a total of 0.00 from holding RespireRx Pharmaceuticals or generate 0.0% return on investment over 90 days. RespireRx Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than RespireRx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
RespireRx Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for RespireRx Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as RespireRx Pharmaceuticals, and traders can use it to determine the average amount a RespireRx Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| RSPI |
Based on monthly moving average RespireRx Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of RespireRx Pharmaceuticals by adding RespireRx Pharmaceuticals to a well-diversified portfolio.
RespireRx Pharmaceuticals Fundamentals Growth
RespireRx Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of RespireRx Pharmaceuticals, and RespireRx Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RespireRx Pink Sheet performance.
| Return On Asset | -8.34 | ||||
| Current Valuation | 3.18 M | ||||
| Shares Outstanding | 119.59 M | ||||
| Price To Earning | (0.25) X | ||||
| Price To Sales | 1,051 X | ||||
| EBITDA | (2.42 M) | ||||
| Cash And Equivalents | 21 | ||||
| Total Debt | 2.42 M | ||||
| Book Value Per Share | (0.1) X | ||||
| Cash Flow From Operations | (956.17 K) | ||||
| Earnings Per Share | (0.04) X | ||||
| Total Asset | 208.74 K | ||||
| Retained Earnings | (156.09 M) | ||||
| Current Asset | 157 K | ||||
| Current Liabilities | 5.05 M | ||||
About RespireRx Pharmaceuticals Performance
By evaluating RespireRx Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into RespireRx Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if RespireRx Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if RespireRx Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey. Respirerx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about RespireRx Pharmaceuticals performance evaluation
Checking the ongoing alerts about RespireRx Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for RespireRx Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RespireRx Pharmaceuticals is not yet fully synchronised with the market data | |
| RespireRx Pharmaceuticals has some characteristics of a very speculative penny stock | |
| RespireRx Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| RespireRx Pharmaceuticals currently holds 2.42 M in liabilities. RespireRx Pharmaceuticals has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist RespireRx Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, RespireRx Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RespireRx Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RespireRx to invest in growth at high rates of return. When we think about RespireRx Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3.14 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| RespireRx Pharmaceuticals currently holds about 21 in cash with (956.17 K) of positive cash flow from operations. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing RespireRx Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RespireRx Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining RespireRx Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RespireRx Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of RespireRx Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of RespireRx Pharmaceuticals' pink sheet. These opinions can provide insight into RespireRx Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in RespireRx Pink Sheet
If you are still planning to invest in RespireRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RespireRx Pharmaceuticals' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |